Literature DB >> 7477623

Secondary hyperparathyroidism and depression in chronic renal failure.

M Driessen1, T Wetterling, T Wedel, R Preuss.   

Abstract

UNLABELLED: This study was aimed at examining the relation between secondary hyperparathyroidism (sHPT) and depressive syndromes in chronic renal failure (CRF). SAMPLE AND METHODS: 59 chronic CRF patients and 16 depressive patients without CRF were included. Parathyroid hormone (PTH), calcium and phosphate as well as psychopathology were measured.
RESULTS: Depressive CRF patients with cognitive disorders show higher levels of PTH than less or not depressive subjects. With respect to the literature, our results give reason to assume that sHPT may play a pathogenetic role in those depressive syndromes which are additionally characterized by cognitive disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477623     DOI: 10.1159/000188614

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

Review 1.  Parathyroid hormone, cognitive function and dementia: a systematic review.

Authors:  Ilianna Lourida; Jo Thompson-Coon; Chris M Dickens; Maya Soni; Elżbieta Kuźma; Katarina Kos; David J Llewellyn
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

2.  Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?

Authors:  Michael Berger; Michael Riedel; Nora Tomova; Michael Obermeier; Florian Seemüller; Sandra Dittmann; Hans-Jürgen Moeller; Emanuel Severus
Journal:  Int J Bipolar Disord       Date:  2013-06-14

3.  Neurological, psychological, and cognitive disorders in patients with chronic kidney disease on conservative and replacement therapy.

Authors:  Silvia Lai; Oriano Mecarelli; Patrizia Pulitano; Roberto Romanello; Leonardo Davi; Alessia Zarabla; Amalia Mariotti; Maria Carta; Giorgia Tasso; Luca Poli; Anna Paola Mitterhofer; Massimo Testorio; Nicla Frassetti; Paola Aceto; Alessandro Galani; Carlo Lai
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.